RegenLab USA, which provides medical devices for tissue repair and other regenerative medicinal uses, filed on Friday with the SEC to raise up to $35 million in an initial public offering.RegenLab ...
Investing.com -- RegenLab USA, Inc., a Swiss-founded regenerative medicine developer specializing in point-of-care cell processing devices, has filed a Form S-1 registration statement with the SEC to ...
2026年9月底，RegenLab USA向美国SEC递交了招股文件，计划在纳斯达克上市。
從財務業績來看，公司營收呈現加速增長態勢。截至2026年6月30日止的六個月內，淨產品銷售額按年增長21%，達到2,932萬美元。營收的擴張推動公司重返盈利軌道，實現營業收入210萬美元，淨利潤7.1萬美元，而上年同期分別錄得營業虧損77萬美元及淨虧損3.2萬美元。2025年全年營收達到4,917萬美元，但由於研發支出增加，全年淨虧損為124萬美元。
נתחו את התיוק על ידי שדרוג ל-InvestingPro - קבלו 50% הנחה היום החברה נוסדה על ידי יו"ר הדירקטוריון והמנכ"ל Antonino Turzi, המחזיק ב-98.64% מכוח ההצבעה, ו-RegenLab מפעילה מרכזי מחקר ופיתוח וייצור ...
Mali sonuçlar, hızlanan üst satır momentumunu öne çıkarıyor. 30 Haziran 2026’da sona eren altı aylık dönemde net ürün satışları yıllık bazda yüzde 21 artarak 29,32 milyon dolara yükseldi. Gelir artışı ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results